A number of rare/genetic disease readouts are set this Q3 2025. Some of them are likely to move big. See table below for 6 of the anticipated readouts. 📈 📉 6 stocks likely to move big on rare/genetic disease readouts in Q3 ‘25 👇    $ARCT ARCT-032 / Cystic Fibrosis / Phase 2 » Safety findings → No SAEs, severe AEs, or dose-limiting toxicities → Dose-related increase in transient, mild, post-dose respiratory symptoms » PK findings: Very low systemic exposure → mRNA: all plas

A number of rare/genetic disease readouts are set this Q3 2025. Some of them are likely to move big. See table below for 6 of the anticipated readouts. 📈 📉

(Posted 10am CST) $XBI $81.76 | -3.16% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

(Posted 10am CST) $XBI $81.76 | -3.16% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

The 40th Annual J.P. Morgan Health Care Conference is taking place fully online from January 10-13, 2022. "This premier conference is...